Amyloid Plaque News and Research

RSS

Pre-clinical study results of EVP-0015962 presented at AAICAD 2010

EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2010 International Conference on Alzheimer's Disease results from its proprietary gamma-secretase modulator pre-clinical study. In a transgenic mouse model, EnVivo's EVP-0015962 reduced amyloid plaque buildup which is believed to be a cause of Alzheimer's disease, reversed behavioral deficits and reduced brain inflammation associated with Alzheimer's disease.

15 Jul 2010

Syntermed releases NeuroQ version 3.5 for analysis, image display of brain FDG-PET scans

At the Alzheimer's Association 2010 International Conference (ICAD) July 10-14 in Honolulu, HI, Syntermed, Inc. launched NeuroQ™ version 3.5, a nuclear medicine quantitative software platform for analysis and image display of brain FDG-PET scans. NeuroQ can increase physician accuracy in diagnosing and differentiating the many types of dementia, compared to visual interpretation alone of FDG-PET.

12 Jul 2010

Researcher uses biopharmaceutical proteases to develop novel therapy for Alzheimer's disease

A University of Oklahoma researcher is developing a novel therapy for Alzheimer's disease using "biopharmaceutical proteases" to attack the toxic plaque that builds up in the brain of an Alzheimer's patient-an approach that he predicts will be lower in cost and higher in effectiveness than current therapies.

9 Jul 2010

Scientists discover characteristic amyloid plaques in retinas from Alzheimer's disease patients

The nerve cell-damaging plaque that builds up in the brain with Alzheimer's disease also builds up in the retinas of the eyes - and it shows up there earlier, leading to the prospect that noninvasive optical imaging of the eyes could lead to earlier diagnosis, intervention and monitoring of the disease, according to new research.

25 Jun 2010

Research analyzes clinical connection of NPH to AD

Normal Pressure Hydrocephalus is a neurological condition which typically affects adults ages 55 and older. This condition was first described in the 1960s as a triad of gait disturbance, dementia, and bladder incontinence. The ventricles of the brain appear enlarged although the cerebrospinal fluid pressure remains normal.

5 May 2010

High sensitivity of Zetasizer Nano proves essential for protein aggregation studies

Dr Martin Muschol, Assistant Professor at the University of South Florida’s (USF) Department of Physics and his team are carrying out important research to gain a better understanding of protein aggregation phenomena, including protein crystallization and amyloid fibril growth. Using the Zetasizer Nano ZS, from Malvern Panalytical (Malvern Panalytical, UK), the USF researchers have been able to perform temperature controlled static and dynamic light scattering (DLS) measurements of protein hydration, protein interactions and aggregation kinetics in vitro.

From Malvern Panalytical 15 Apr 2010

Interim data from Avid's florbetapir "Image-to-Autopsy" Phase III study to be presented

Avid Radiopharmaceuticals, Inc. today announced the presentation of interim data from its landmark florbetapir "Image-to-Autopsy" Phase III study. These data come from the first cohort of subjects in the trial and are the first ever Phase III results for an agent designed to image Alzheimer's disease pathology.

15 Apr 2010

Avid Radiopharmaceuticals, PETNET Solutions collaborate in manufacture of Florbetapir F 18

Avid Radiopharmaceuticals, Inc. and PETNET Solutions, Inc., a wholly-owned subsidiary of Siemens Medical Solutions, USA, Inc., marked the first dose shipped from a PETNET Solutions manufacturing facility as part of its collaboration with Avid on Florbetapir F 18 (18F-AV-45 or Florbetapir), Avid's molecular imaging agent for positron emission tomography (PET) imaging of β-amyloid deposits in the brain, a key pathological component of Alzheimer's disease.

8 Apr 2010

Avid, Cardinal Health partner to detect Alzheimer's disease in living patients

Currently, Alzheimer's disease cannot be definitively diagnosed until after death, when a brain autopsy is performed on a patient and evidence of beta-amyloid plaque deposits in the brain – which are a characteristic pathology of the disease – can be found. Accurate diagnosis during life can be challenging, particularly in the early stages of Alzheimer's, when symptoms are mild and non-definitive. However, Avid Radiopharmaceuticals, Inc. and Cardinal Health are working together to change that.

26 Mar 2010

UC Irvine researchers play leading role in genome sequencing of Hydra

UC Irvine researchers have played a leading role in the genome sequencing of Hydra, a freshwater polyp that has been a staple of biological research for 300 years.

15 Mar 2010

High methionine diet may increase risk of dementia

A diet rich in methionine, an amino acid typically found in red meats, fish, beans, eggs, garlic, lentils, onions, yogurt and seeds, can possibly increase the risk of developing Alzheimer's disease, according to a study by Temple researchers.

17 Dec 2009

Brain inflammation not linked to Alzheimer's disease

In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease.

23 Oct 2009

Eyes may mirror Alzheimer's disease

The eyes may be the windows to the soul, but new research indicates they also may mirror a brain ravaged by Alzheimer's disease.

22 Oct 2009

Chronic sleep deprivation linked to early incidence of Alzheimer's brain plaques

Chronic sleep deprivation in a mouse model of Alzheimer's disease makes Alzheimer's brain plaques appear earlier and more often, researchers at Washington University School of Medicine in St. Louis report online this week in Science Express.

25 Sep 2009

Discovery of a new Alzheimer's gene

A UC Irvine study has found that a gene called TOMM40 appears twice as often in people with Alzheimer's disease than in those without it. Alzheimer's, for which there is no cure, is the leading cause of elderly dementia.

6 Aug 2009

Potential new treatment for Alzheimer’s

Indeed, these carriers tend to develop the disease later than others, but when that happens, it progresses more rapidly and does not respond to medication. Therefore, the bottom line is that carriers of the mutated gene have a greater risk than others for disease progression.

20 Jul 2009

Preliminary findings in Phase IIA trial point to natural compound NIC5-15's potential in Alzheimer's disease

Researchers at Mount Sinai School of Medicine have found that a compound called NIC5-15, might be a safe and effective treatment to stabilize cognitive performance in patients with mild to moderate Alzheimer's disease.

19 Jul 2009

Discovery of novel receptor in the brain, potential target for Alzheimer's

Barrow Neurological Institute researchers have identified a novel receptor in the brain that is extremely sensitive to beta-amyloid peptide (AB) and may play a key role in early stages of Alzheimer's disease.

17 Jul 2009

Turmeric spice and vitamin D may help clear amyloid plaques found in Alzheimer's

UCLA scientists and colleagues from UC Riverside and the Human BioMolecular Research Institute have found that a form of vitamin D, together with a chemical found in turmeric spice called curcumin, may help stimulate the immune system to clear the brain of amyloid beta, which forms the plaques considered the hallmark of Alzheimer's disease.

15 Jul 2009

Brain imaging (MRI/PET) bring us closer to earlier detection of Alzheimer's

Changes in the brain measured with MRI and PET scans, combined with memory tests and detection of risk proteins in body fluids, may lead to earlier and more accurate diagnosis of Alzheimer's, according to new research reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.

14 Jul 2009